Pharmaceutical composition for the treatment or prevention of a malignant tumor
AssigneeTransgene S.A.
InventorsPierre Chambon, Marie-Paule Kieny, Richard Lathe, Mara Hareuveni
Life of this patent
Estimating the term…
Abstract
The application provides a polypeptide and a pharmaceutical composition which comprises said polypeptide, wherein said polypeptide is recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells. This antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the polypeptides specifically bound by antibody H23.
Claims40
A pharmaceutical composition which comprises, as therapeutic agent, a polypeptide recognized by antibody H23, said polypeptide comprising a sequence repeated n times, n being a number from 1 to 80;
- and of formula (I):
- Pro—Gly—Ser—Thr—Ala—Pro—X1—Ala—His—Gly—Val—Thr—Ser—Ala—Pro—Asp—Y—Arg—Pro—X2 (SEQ ID NO:
- 3) in which X1, and X2 are, independently, Pro or Ala and Y is Thr or Asn;
- and said polypeptide comprising a sequence selected from the group consisting of (i) the sequence as shown in SEQ ID NO:
- 2 beginning with the threonine residue at position 22 and ending with the leucine residue at position 2035 or a sequence identical thereto except that the number of repeated sequences having SEQ ID NO:
- 3 ranges from 1 to 79, (ii) the sequence as shown in SEQ ID NO:
- 5 beginning with the threonine residue at position 22 and ending with the proline residue at position 1867, or a sequence identical thereto, except that the number of repeated sequences having SEQ ID NO:
- 3 ranges from 1 to 79, (iii) variants of the sequences set forth in (i) or (ii), wherein such variants differ from the sequence set forth in (i) or (ii), only in the fact that one or more of the repeat sequences contained therein differs from the repeat sequence of SEQ ID NO:
- 3 at no more than three amino acid positions, and (iv) fragments of any of said sequences set forth in (i), (ii) or (iii), wherein said fragment is a polypeptide that is recognized by antibody H23, and a pharmaceutically acceptable diluent or vehicle.
A polypeptide which comprises a sequence repeated n times, n being a number from 1 to 4;
- and of formula (I):
- Pro—Gly—Ser—Thr—Ala—Pro—X1—Ala—His—Gly—Val—Thr—Ser—Ala—Pro—Asp—Y—Arg—Pro—X2 (SEQ ID NO:
- 3) in which X1 and X2 are, independently, Pro or Ala and Y is Thr or Asn;
- and said polypeptide comprising a sequence selected from the group consisting of (i) the sequence as shown in SEQ ID NO:
- 2 beginning with the threonine residue at position 22 and ending with the leucine residue at position 2035 or a sequence identical thereto except that the number of repeated sequences having SEQ ID NO:
- 3 ranges from 1 to [4, (ii) the sequence as shown in SEQ ID NO:
- 5 beginning with the threonine residue at position 22 and ending with the proline residue at position 1867, or a sequence identical thereto, except that the number of repeated sequences having SEQ ID NO:
- 3 ranges from 1 to 4, (iii) variants of the sequences set forth in (i) or (ii), wherein such variants differ from the sequence set forth in (i) or (ii), only in the fact that one or more of the repeat sequences contained therein differs from the repeat sequence of SEQ ID NO:
- 3 at no more than three amino acid positions, and (iv) fragments of any of said sequences set forth in (i), (ii) or (iii), wherein said fragment is a polypeptide that is recognized by antibody H23.
A composition which comprises a polypeptide recognized by antibody H23, said polypeptide comprising a sequence repeated n times, n being a number from 1 to 4;
- and of formula (I):
- Pro—Gly—Ser—Thr—Ala—Pro—X1—Ala—His—Gly—Val—Thr—Ser—Ala—Pro—Asp—Y—Arg—Pro—X2 SEQ ID NO:3 in which X1 and X2 are, independently, Pro or Ala and Y is Thr or Asn;
- and said polypeptide comprising a sequence selected from the group consisting of (i) the sequence as shown in SEQ ID NO:2 beginning with the threonine residue at position 22 and ending with the leucine residue at position 2035 or a sequence identical thereto except that the number of repeated sequences having SEQ ID NO:3 ranges from 1 to 4, (ii) the sequence as shown in SEQ ID NO:5 beginning with the threonine residue at position 22 and ending with the proline residue at position 1867, or a sequence identical thereto, except that the number of repeated sequences having SEQ ID NO:3 ranges from 1 to 4, (iii) variants of the sequences set forth in (i) or (ii), wherein such variants differ from the sequence set forth in (i) or (ii), only in the fact that one or more of the repeat sequences contained therein differs from the repeat sequence of SEQ ID NO:3 at no more than three amino acid positions, and (iv) fragments of any of said sequences set forth in (i), (ii) or (iii), wherein said fragment is a polypeptide that is recognized by antibody H23.
Dependencies are inferred from the claim text.